ScholarLens Back to search
2022•Blood AdvancesOpen access

A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia

Alessandro Broccoli, Lisa Argnani, Matt Cross, Agnieszka Januś, Elsa Maître, Xavier Troussard, Tadeusz Robak, Claire E. Dearden, Monica Else, Daniel Catovsky, Pier Luigi Zinzani

Open full text 19 citations

Abstract

Key Points Cladribine is regarded as the first treatment of choice for symptomatic hairy cell leukemia. This large international study reports a complete response in 72% of cases and a continuous complete response in 20% of patients.

Open-access reader

About this research paper

What this paper is about

Key Points Cladribine is regarded as the first treatment of choice for symptomatic hairy cell leukemia. This large international study reports a complete response in 72% of cases and a continuous complete response in 20% of patients.

Why it matters

OpenAlex reports 19 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key Points Cladribine is regarded as the first treatment of choice for symptomatic hairy cell leukemia. This large international study reports a complete response in 72% of cases and a continuous complete response in 20% of patients.

Key concepts: Cladribine, Hairy cell leukemia, Medicine, Leukemia, Multicenter study, Internal medicine, Oncology, Randomized controlled trial

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia — Research Paper | ScholarLens